There is no evidence that I'm aware of that supports this view. I have Myelofibrosis, diagnosed 2003, and have been on Interferon Alpha since that time. However, I do believe it has played a significant role in extending my lifespan.
Thank you very much Geoff Ring for sharing your experience but can you tell me what type of interferon alpha you recieve is it the pegylated or the conventional what dose and what is the risk stratification as per DIPSS
Hi Mohamed,
I'm on the borderline between Intermediate 1 and Intermediate 2 using the DIPSS plus scoring model. I'm over 65 (one point) and my haemoglobin is under 100 (which is two points ), so technically I'm Intermediate 2. However, my last blood test gave me a 102 for Hgb, and I'm only 66, hence my conclusion that I'm on the borderline.
I don't use any of the pegylated versions of Interferon because they are not available to me in Australia. I self-inject 'standard' Interferon three times per week (3 million units each time). I used to use Intron-A (alpha 1b) but was required to switch to Roferon A (alpha 1a) as it cost the pharmacy less. I can't complain because I only pay about $30 for 3 months supply because of the government subsidy.
Geoff
Dear Geoff Thank you very much for your detailed answer its really interesting to hear from colleagues their valuable experience
Dear Mohamed
These articles may be useful for you:
1) Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation.
Dagorne A, Douet-Guilbert N, Quintin-Roue I, Guillerm G, Couturier MA, Berthou C, Ianotto JC.
Ann Hematol. 2013 Mar;92(3):407-9.
Interferon is a man-made copy of a protein that is produced by the body in response to infection. It helps the immune system fight disease. Interferon may be used to treat some leukemias Interferon do not directly kill viral or cancerous cells. It boosts the immune system response and reduces the growth of cancer cells by regulating the action of several genes that control the secretion of numerous cellular proteins that affect growth. Starting in 1966 (with a peak in the 1980s and 1990s) the results of several clinical studies on the antineoplastic activity of interferon alpha in acute myeloid leukaemia patients have been published. It is observed the use of interferon may increase the survival rate of some people with melanoma. However, recent insights into the key pharmacokinetic determinants of the clinical efficacy of Interferon along with advances in its pharmaceutical formulation have sparked renewed interest in its use.
- Badges
- Science topic
- Similar topics
- Biological Science
- Microbiology
- Virology
- Virus